Uncategorized
ROTATE study shows letter gain in DME patients who switch anti-VEGF agents
VIENNA — Six-month results of the Genentech-sponsored ROTATE trial showed benefits of switching to ranibizumab 0.3 mg in patients with diabetic macular edema after recent, frequent and long-term treatment with bevacizumab. “Switching from Avastin to Lucentis in DME and other macular diseases is a common clinical scenario. However, prospective evaluations of DME switchers studies are usually not robust and usually have significant anti-VEGF washout periods,” Dennis Marcus, MD, said at the American Society of Retina Specialists meeting.